Navigation Links
Enbrel Will Remain Decision Resources' Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
Date:1/12/2010

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer/Takeda's Enbrel will retain Decision Resources' proprietary clinical gold standard status for the treatment of rheumatoid arthritis through 2018. Although Centocor Ortho Biotech/Merck/Mitsubishi Tanabe/Janssen's Simponi offers delivery advantages over Enbrel in formulation (potentially offered in both subcutaneous and intravenous formulations) and dosing frequency (once monthly compared with once or twice weekly for Enbrel), neither Simponi nor any other rheumatoid arthritis biologic have the same effect as Enbrel in inhibiting/slowing structural damage progression.

The new report entitled Rheumatoid Arthritis: Opportunity Awaits Therapies that Meet Physicians' Efficacy Expectations in TNF-α Inhibitor-Refractory Patients also finds that rheumatologists are unwilling to compromise on efficacy or convenient delivery for a disease-modifying drug with a novel mechanism of action for patients who are refractory to tumor necrosis factor alpha (TNF-alpha) inhibitors, even if such an agent entered the market at a lower price point than leading biologics. Surveyed U.S. rheumatologists stated that such a drug (that doesn't compromise on efficacy) could be prescribed to 63 percent of eligible U.S. patients. Surveyed European rheumatologists indicated that such an agent could be prescribed to 75 percent of eligible European patients.

"Because we believe the TNF-alpha inhibitors will remain the most prescribed treatments for patients who have failed or lost response to conventional disease-modifying antirheumatic drugs, we profiled the opportunity for an agent in the TNF-alpha inhibitor-refractory population in our study. High price, intravenous delivery route and the potential for harmful side-effects are all drawbacks to current biologic agents used to treat TNF-alpha inhibitor-refractory patients. However, given a drug with incremental safety, delivery and even cost advantages, physicians are still unwilling to compromise on efficacy," stated Decision Resources Analyst Kyle Crowell.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Can Your Drug Gain An Edge in the TNF-Alpha Refractory Patient Segment of the Rheumatoid Arthritis Market? Exploring Drug Attributes Needed to Maximize Patient Share. This webinar will be held on Wednesday, January 27, 2010 at 10 a.m. U.S. Eastern Time. For more information, please contact Gisselle Morales at 781-296-2691 or by email at gmorales@dresources.com.

About the Report

Rheumatoid Arthritis: Opportunity Awaits Therapies that Meet Physicians' Efficacy Expectations in TNF-α Inhibitor-Refractory Patients is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

SOURCE Decision Resources

RELATED LINKS
http://www.decisionresources.com

'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
2. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
3. Senate Rejects Bulk Imports of Medicine from Canada, but Personal Importation Remains a Popular Option for U.S. Citizens
4. Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing From $360 Million in 2008 to $450 Million in 2018
5. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
6. Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
7. U.S. Naval Medical Research Center Proposed RESUS Clinical Trial in Trauma Patients Remains on FDA Hold
8. For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold
9. Cardiac Disease in Women Remains Untreated for Decades
10. Quality Colonoscopy Exam Remains Best Strategy for Detection of Polyps and Cancers According to Experts From the American College of Gastroenterology
11. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... programs. The hands-on learning experience is a 12-week summer ... Fellowship and Internship programs bring ... and interns are provided optional housing free of charge ... at the Riverfront Residence Hall to foster communication and ...
(Date:5/23/2016)... May 23, 2016 Non-invasive diagnostic ... of multiple diseases; ,Technology to be presented at Yissum’s ... Yissum Research Development Company of the Hebrew University of ... research agreement with Aurum Ventures MKI, the technology investment arm ... a new diagnostic approach for early detection of multiple ...
(Date:5/22/2016)... May 23, 2016 DS ... anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive ... non-alcoholic steatohepatitis (NASH) patients. Recent DS ... in lung tissue and has bronchodilatory, anti-inflammatory and ... administration. The Company will publish further detail on ...
Breaking Medicine Technology:
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... Controlling ... smarter - with the launch of the Aquanta Water Heater Controller , a ... smart phone or web-enabled device. As the Nest thermostat does for HVAC systems, ...
(Date:5/24/2016)... WI (PRWEB) , ... May 24, 2016 , ... ... In Milwaukee , Out patient Services To Begin In June , Aloria Health, ... pleased to announce the opening of Aloria Milwaukee, its first treatment facility for ...
(Date:5/24/2016)... NJ (PRWEB) , ... May 24, 2016 , ... The ... that’s causing the problem. A common injury that’s often misunderstood, whiplash should be swiftly ... MD, a Harvard-trained, orthopedic spine surgeon at Atlantic Spine Center . , ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... successful implementation of protocols designed to reduce bleeding complications from percutaneous coronary intervention ... Angiography and Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Essette Dashboard, its highly anticipated, web-based software module. The cutting-edge feature provides ... “secret sauce”? Integration with Izenda’s self-service business intelligence solution and its analytics ...
Breaking Medicine News(10 mins):